1. The diagnosis value of endobronchial ultrasound transbronchial lung biopsy combined with rapid on‐site evaluation in peripheral lung cancer
- Author
-
Qian Zhang, Ji Wang Wang, Chuan Zhen Chi, Qi Yuan, Chunhua Xu, Wei Wang, Xiu Wei Zhang, and Yuchao Wang
- Subjects
Adult ,Image-Guided Biopsy ,Male ,Pulmonary and Respiratory Medicine ,China ,medicine.medical_specialty ,Lung Neoplasms ,Time Factors ,Site evaluation ,Endosonography ,03 medical and health sciences ,0302 clinical medicine ,Bronchoscopy ,Biopsy ,medicine ,Humans ,Immunology and Allergy ,Prospective Studies ,030212 general & internal medicine ,Endobronchial ultrasound ,Lung cancer ,Lung ,Genetics (clinical) ,Aged ,Peripheral lung cancer ,medicine.diagnostic_test ,business.industry ,Transbronchial lung biopsy ,Middle Aged ,medicine.disease ,030228 respiratory system ,Female ,Radiology ,Tomography, X-Ray Computed ,business ,Complication - Abstract
INTRODUCTION Rapid on-site evaluation (ROSE) has the potential to increase endobronchial ultrasound transbronchial lung biopsy with guide sheath (EBUS-GS-TBLB) accuracy in the diagnosis of peripheral lung cancer. However, studies have reported controversial results. OBJECTIVES The aim of the study was to evaluate the diagnosis value of EBUS-GS-TBLB combination with ROSE in peripheral lung cancer. METHODS A total of 138 patients undergoing EBUS-GS-TBLB and ultimately diagnosed with lung cancer were allocated into the ROSE group and non-ROSE group. The result of the diagnostic yields, number of biopsy sites, the complication, cytopathological diagnostic cost and procedure times of EBUS-GS-TBLB with ROSE and without ROSE were compared. RESULTS The diagnostic yields of TBLB were 87.8% and 78.1% in ROSE group and non-ROSE group, respectively (P
- Published
- 2020
- Full Text
- View/download PDF